RS66072B1 - Nova upotreba agonista angiotenzinskog ii receptora tipa 2 - Google Patents
Nova upotreba agonista angiotenzinskog ii receptora tipa 2Info
- Publication number
- RS66072B1 RS66072B1 RS20241153A RSP20241153A RS66072B1 RS 66072 B1 RS66072 B1 RS 66072B1 RS 20241153 A RS20241153 A RS 20241153A RS P20241153 A RSP20241153 A RS P20241153A RS 66072 B1 RS66072 B1 RS 66072B1
- Authority
- RS
- Serbia
- Prior art keywords
- respiratory
- virus
- use according
- compound
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2004209.9A GB202004209D0 (en) | 2020-03-23 | 2020-03-23 | New use |
| GBGB2009574.1A GB202009574D0 (en) | 2020-06-23 | 2020-06-23 | New use |
| US17/113,416 US11123329B1 (en) | 2020-03-23 | 2020-12-07 | Use of angiotensin II type 2 receptor agonist |
| EP21715306.3A EP4125881B1 (en) | 2020-03-23 | 2021-03-22 | New use of angiotensin ii type 2 receptor agonist |
| PCT/GB2021/050699 WO2021191592A1 (en) | 2020-03-23 | 2021-03-22 | New use of angiotensin ii type 2 receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66072B1 true RS66072B1 (sr) | 2024-11-29 |
Family
ID=77747178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20241153A RS66072B1 (sr) | 2020-03-23 | 2021-03-22 | Nova upotreba agonista angiotenzinskog ii receptora tipa 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123329B1 (https=) |
| EP (1) | EP4125881B1 (https=) |
| JP (1) | JP7671305B2 (https=) |
| CN (1) | CN115605201A (https=) |
| CA (1) | CA3176108A1 (https=) |
| ES (1) | ES2992423T3 (https=) |
| HR (1) | HRP20241435T1 (https=) |
| HU (1) | HUE068662T2 (https=) |
| PL (1) | PL4125881T3 (https=) |
| RS (1) | RS66072B1 (https=) |
| SM (1) | SMT202400427T1 (https=) |
| WO (1) | WO2021191592A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| US20220233480A1 (en) * | 2020-03-23 | 2022-07-28 | Vicore Pharma Ab | Use of angiotensin ii type 2 receptor agonist |
| AU2021258178A1 (en) * | 2020-04-22 | 2022-11-17 | Airway Therapeutics, Inc. | Use of surfactant protein D to treat viral infections |
| US20240408065A1 (en) * | 2021-09-30 | 2024-12-12 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Cyano compound, and preparation method therefor and use thereof |
| CN115583984A (zh) * | 2022-01-11 | 2023-01-10 | 嘉兴安谛康生物科技有限公司 | 氮杂螺类化合物及其制备方法、药物组合物和用途 |
| CN114948950A (zh) * | 2022-01-19 | 2022-08-30 | 广州谷森制药有限公司 | 一种药物组合物及其抗病毒用途 |
| WO2024153020A1 (zh) * | 2023-01-16 | 2024-07-25 | 海南先声药业有限公司 | 抗病毒药物组合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1529697B (zh) | 2001-05-31 | 2010-09-22 | 维科尔药物公司 | 用作血管紧张素ⅱ激动剂的三环化合物 |
| EP1723962A1 (en) | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
| EP3265082A1 (en) | 2015-03-02 | 2018-01-10 | Vicore Pharma AB | Angiotensin ii receptor agonist for treating pulmonary fibrosis |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
-
2020
- 2020-12-07 US US17/113,416 patent/US11123329B1/en active Active
-
2021
- 2021-03-22 EP EP21715306.3A patent/EP4125881B1/en active Active
- 2021-03-22 WO PCT/GB2021/050699 patent/WO2021191592A1/en not_active Ceased
- 2021-03-22 CA CA3176108A patent/CA3176108A1/en active Pending
- 2021-03-22 SM SM20240427T patent/SMT202400427T1/it unknown
- 2021-03-22 RS RS20241153A patent/RS66072B1/sr unknown
- 2021-03-22 PL PL21715306.3T patent/PL4125881T3/pl unknown
- 2021-03-22 HR HRP20241435TT patent/HRP20241435T1/hr unknown
- 2021-03-22 ES ES21715306T patent/ES2992423T3/es active Active
- 2021-03-22 JP JP2022557150A patent/JP7671305B2/ja active Active
- 2021-03-22 HU HUE21715306A patent/HUE068662T2/hu unknown
- 2021-03-22 CN CN202180035480.3A patent/CN115605201A/zh active Pending
- 2021-08-27 US US17/458,886 patent/US20210386712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2992423T3 (es) | 2024-12-12 |
| JP7671305B2 (ja) | 2025-05-01 |
| US11123329B1 (en) | 2021-09-21 |
| CN115605201A (zh) | 2023-01-13 |
| EP4125881A1 (en) | 2023-02-08 |
| JP2023520323A (ja) | 2023-05-17 |
| US20210386712A1 (en) | 2021-12-16 |
| EP4125881C0 (en) | 2024-07-24 |
| CA3176108A1 (en) | 2021-09-30 |
| SMT202400427T1 (it) | 2024-11-15 |
| HUE068662T2 (hu) | 2025-01-28 |
| PL4125881T3 (pl) | 2024-12-02 |
| US20210290596A1 (en) | 2021-09-23 |
| HRP20241435T1 (hr) | 2024-12-20 |
| WO2021191592A1 (en) | 2021-09-30 |
| EP4125881B1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4125881B1 (en) | New use of angiotensin ii type 2 receptor agonist | |
| RU2766577C2 (ru) | Способы лечения эозинофильного эзофагита | |
| US11364227B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection | |
| US20110293686A1 (en) | Anti-viral compositions and methods for administration | |
| US20230129866A1 (en) | Methods of treating respiratory disease with deupirfenidone | |
| JP2013529627A (ja) | ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置 | |
| WO2012104402A1 (en) | Treatment of severe persitent asthma with masitinib | |
| AU2022245186A1 (en) | Treatment of hidradenitis suppurativa with orismilast | |
| Shuhui et al. | Jinyinqingre Oral Liquid alleviates LPS-induced acute lung injury by inhibiting the NF-κB/NLRP3/GSDMD pathway | |
| US20230158103A1 (en) | Pld for use in combination in the treatment of coronavirus | |
| CN113260363A (zh) | 格拉普兰特(grapiprant)单位剂型 | |
| US20220233480A1 (en) | Use of angiotensin ii type 2 receptor agonist | |
| Lu et al. | Long course of low-dose dexamethasone following or after bleomycin administration ameliorates pulmonary fibrosis | |
| HK40081689A (en) | New use of angiotensin ii type 2 receptor agonist | |
| HK40081689B (en) | New use of angiotensin ii type 2 receptor agonist | |
| TW202144380A (zh) | 用於治療冠狀病毒感染之化合物 | |
| US11471448B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia | |
| WO2021204814A1 (en) | Nachr, such as nicotine, for use in the prevention and the treatment of covid-19 disease | |
| Rodriguez et al. | The combination of inhaled budesonide and formoterol as an early treatment for the covid-19 disease | |
| WO2023192779A2 (en) | Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections |